TheraVasc is developing a repurposed drug, TV1001, an oral formulation of sodium nitrite, to target patient populations with poor blood flow to the extremities, such as those with diabetic leg and foot problems or those with peripheral artery disease (PAD). While there is a large and growing number of patients suffering from such health problems, there is no effective treatment available. TV1001 has been shown to selectively promote the re-growth of blood vessels in ischemic tissues such as those affected in patients with diabetes or PAD. TheraVasc has received investment from the North Coast Angel Fund, Jumpstart Evergreen, Focus, and Next Funds, and GLIDE.
SironRX Therapeutics was developing novel therapies to promote dermal wound repair and reduce scarring. The company’s therapeutic platform was based on the delivery of Stromal cell-Derived Factor 1 (SDF-1), which has been shown to promote tissue repair by recruiting stem cells to the damaged organ. SDF-1 has also been shown to prevent cell death and promote new blood vessel formation. SironRx Therapeutics has received investment from the North Coast Angel Fund, Cleveland Clinic, and Jumpstart Next, Evergreen, and Focus Funds.
Neuros Medical, a Cleveland-based neurostimulation company, is focused on developing neurostimulation therapies for unmet needs to patients worldwide. The company’s platform technology, Electrical Nerve Block, works to eliminate chronic pain and spasticity in a variety of applications, including neuroma/residual limb pain, chronic post surgical pain, and chronic migraine. Neuros has received investment from the North Coast Angel Fund and the Jumpstart Evergreen, Focus, and Next Funds.
NanoVision Diagnostics is commercializing a breakthrough cancer technology that can sooner detect and more accurately predict the risk of progression through the optical analysis of a standard biopsy slide. Their patented microscope has 1000x better sensitivity than an optical microscope, enabling it to detect molecular scale changes that are not visible through conventional pathology. Molecular changes manifest prior to cellular changes, allowing earlier and more accurate detection. The company is initially focused on the detection and prognosis of breast cancer, with plans to expand to the study of multiple cancer strains in the future. NanoVision Diagnostics has received investment from the North Coast Angel Fund.
Great Lakes Pharmaceuticals, Inc. is a clinical stage company focused on developing and commercializing products that prevent infections associated with indwelling catheters. Their first product, B-Lock™, is an anticoagulant catheter lock solution that works against the bacterial and fungal microorganisms known to form biofilm structures in catheters. Biofilm-related infections are the 8th leading cause of death in the United States. Headquartered in Concord, OH with offices in San Diego, CA, Great Lakes Pharmaceuticals assembled teams of experienced and distinguished scientists, clinicians, and managers to assure a smooth development as well as the commercialization of innovative, effective treatments of microbial infections in clinical and outpatient settings. Great Lakes Pharmaceuticals has received investment from the North Coast Angel Fund and the Jumpstart Evergreen, Next, and Focus funds.
GenomOncology is in the personalized medicine space with a proprietary technology platform to rapidly analyze sequenced genomic data for use in cancer treatment. The platform enables users to browse, filter, and map variations at many different levels to discover the genetic mutations that are unique to the tumor. From this analysis, the company generates a customizable report, including findings and clinical recommendations based on the observed actionable mutations in the tumor genome. Considering cancer is a disease of genetic mutation, this type of personalized approach represents the future of oncology. GenomOncology has received investment from the North Coast Angel Fund and the Jumpstart Evergreen, Next, and Focus funds.
Cryothermic Systems (formerly known as LifeCore Technologies) offers the Excel ® Cryo Cooling System for immediate and selective cooling of the brain after cardiac arrest, stroke, or traumatic brain injury. A 2009 Cath Lab Digest study reported that, “for every hour to first cooling, the relative hazard of death increases 29%.” The coolant and collar system was recently honored for its innovative design and ease of use by EMS Pro Magazine and by the Journal of Emergency Medical Services. The company is working to accelerate adoption by hospitals and EMS services. Cryothermic Systems has received funding from the North Coast Angel Fund and the Jumpstart Next, Evergreen, and Focus Funds.
CerviLenz™, Inc., headquartered near Cleveland, Ohio, is a manufacturer and marketer of a patented, FDA-cleared device to predict preterm birth risk in pregnant women by accurately measuring cervical length. Preterm birth (delivery prior to 37 completed weeks of gestation) affects almost 13 percent of pregnancies annually in the United States, equivalent to over 500,000 babies. Preterm birth is not only the leading cause of infant death, but also increases risk of newborn complications and lifelong disabilities. Cervical length is a powerful predictor of preterm birth risk, as indicated by the National Institutes of Health in a study utilizing a specialized ultrasound probe. The Cervilenz device is a simple, low-cost alternative that can be used by healthcare professionals to identify at-risk women who may benefit from progesterone therapy or further consultation…
CardiOx Corp , based in Columbus, is commercializing a technology that enables a highly sensitive, low-cost, minimally invasive procedure for cardiac shunt assessment using their FDSTM Flow Detection System, which has received CE Mark approval with Europe and FDA regulatory clearance in the USA. CardiOX has received investment from the North Coast Angel Fund.
Assurex Health is a personalized medicine company specializing in pharmacogenetics and dedicated to helping physicians determine the right drug at the correct dose for their patients. The proprietary technology is based on pharmacogenetics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology, and produces an easy-to-read report that assist doctors in selecting the appropriate drug and dosage. The company was founded in June 2006 to commercialize industry-leading, personalized medicine technology. Cincinnati Children’s Hospital Medical Center and Mayo Clinic are equity holders and technology collaborators. Assurex Health has received investment from North Coast Angel Fund.